A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
This study is currently recruiting participants.
Verified December 2012 by Allergan
Information provided by (Responsible Party):
First received: December 12, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine Headache patients who have received a minimum of 7 treatment cycles.
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Allergan:
Primary Outcome Measures:
- Number of Headache Days [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01749410
|Contact: Allergan Inc.||firstname.lastname@example.org|
|United States, New York|
|Buffalo, New York, United States|
Sponsors and Collaborators
|Study Director:||Medical Director||Allergan|